Drug intelligence / Profile preview

GSKVX000000048110

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSKVX000000048110 is an investigational influenza vaccine developed by GSK (GlaxoSmithKline Biologicals). It is designed to provide protection against seasonal influenza. The vaccine is typically evaluated in clinical trials to assess its safety, reactogenicity, and immunogenicity in various populations, including healthy adults. As a vaccine, its primary mechanism of action involves the induction of an immune response, specifically the production of antibodies against the hemagglutinin protein of the influenza virus, which prevents the virus from entering host cells and causing infection.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on GSKVX000000048110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSKVX000000048110.

Explore the full profile